Dimolegin (60 mg) Given Once Daily in Patients Undergoing Total Hip or Knee Replacement Compared to Enoxaparin
Status:
COMPLETED
Trial end date:
2025-01-14
Target enrollment:
Participant gender:
Summary
This clinical study aims to evaluate the efficacy and safety of the anticoagulant Dimolegin compared to low molecular weight heparin (Clexane) for the prevention of venous thromboembolic events (VTE) in patients undergoing major joint (hip or knee) replacement surgery. The study will assess the incidence of VTE, VTE-related mortality, and all-cause mortality during different follow-up periods in both treatment groups. Additionally, the study will evaluate the frequency of bleeding events and the incidence, number, and characteristics of all adverse events associated with Dimolegin and Clexane therapy.